Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | 17.01.14 |
Publication Date | 17/01/2014 |
Content Type | News |
In January 2014 the Committee adopted by consensus positive opinions for initial marketing authorisation applications for: Fungitraxx (itraconazole), from Avimedical B.V., an antifungal product for treatment of aspergillosis and candidiasis in identified species of ornamental birds. The product has been classified as MUMS/limited markets; and Equisolon (prednisolone), from LE VET B.V., an anti-inflammatory product for use in horses with recurrent airway obstruction in combination with environmental control. The product has been classified as MUMS/limited markets. |
|
Source Link | http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/01/news_detail_002007.jsp&mid=WC0b01ac058004d5c1 |
Subject Categories | Business and Industry, Health |
Countries / Regions | Europe |
![](https://www.europeansources.info/wp-content/uploads/esologo2.png)